Weems Alonzo
Known title: SVP, ERM & CECOCIK: 0001869672
Associated companies
Transaction History
| LLY | ▲ Buy | Grant | 951 | $701K | 2/12/2024 | View on chart |
| LLY | ▼ Sell | Open Market | 1,148 | $678K | 9/12/2023 | View on chart |
| LLY | ▼ Sell | Gift | 760 | $0 | 9/12/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 1,000 | $319K | 3/10/2023 | View on chart |
| LLY | ▲ Buy | Option Exercise | 1,779 | $0 | 3/1/2023 | View on chart |
| LLY | ▼ Sell | Tax Withholding | 793 | $247K | 3/1/2023 | View on chart |
| LLY | ▲ Buy | Grant | 2,422 | $836K | 2/10/2023 | View on chart |
| LLY | ▼ Sell | Open Market | 656 | $214K | 10/10/2022 | View on chart |
| LLY | ▼ Sell | Gift | 450 | $0 | 10/10/2022 | View on chart |
| LLY | ▼ Sell | Open Market | 656 | $200K | 8/10/2022 | View on chart |
| LLY | ▼ Sell | Gift | 530 | $0 | 8/10/2022 | View on chart |
| LLY | ▲ Buy | Grant | 3,731 | $908K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill
The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.